Grifols, S.A. (GRFS) |
|
11.99 0.09 (0.76%)
|
06-26 18:54 |
|
Open: |
11.92 |
Pre. Close: |
11.9 |
|
High:
|
12.01 |
Low:
|
11.82 |
|
Volume:
|
476,902 |
Market Cap:
|
11,291(M) |
|
|
|
|
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.03 - 12.08 |
12.08 - 12.13 |
|
Low:
|
11.7 - 11.75 |
11.75 - 11.8 |
|
Close:
|
11.91 - 11.99 |
11.99 - 12.09 |
|
Technical analysis |
as of: 2022-06-24 4:40:23 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 14.59 One year: 15.58 |
| Support: |
Support1: 11.13 Support2: 9.26 |
| Resistance: |
Resistance1: 12.49 Resistance2: 13.34 |
| Pivot: |
11.92  |
| Moving Average: |
MA(5): 11.69  MA(20): 12.14
MA(100): 11.66 MA(250): 12.7 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 37.5 %D(3): 27.9 |
| RSI: |
RSI(14): 48.7 |
| 52-week: |
High: 17.45 Low: 10.1 |
| Average Vol(K): |
3-Month: 867 (K) 10-Days: 652 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GRFS ] has closed below upper band by 46.9%. Bollinger Bands are 16.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 24 Jun 2022
Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Veriti Management LLC - Defense World
Thu, 23 Jun 2022
Queen's and PSAC 901 enter arbitration for research assistant job classifications - Queen's Journal
Thu, 23 Jun 2022
Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Thu, 23 Jun 2022
Grifols, S.A. (NASDAQ:GRFS) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Wed, 08 Jun 2022
Grifols Procleix Plasmodium Assay receives CE mark, a first for malaria blood screening - PR Newswire
Sun, 29 May 2022
Grifols, S.A. (NASDAQ:GRFS) Given Average Recommendation of "Hold" by Analysts - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
688 (M) |
| Shares Float |
834 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
42.9 (%) |
|
Shares Short
|
5,940 (K) |
|
Shares Short P.Month
|
4,810 (K) |
Stock Financials |
|
EPS
|
0.14 |
|
EPS Est Next Qtl
|
0.31 |
|
EPS Est This Year
|
1.21 |
|
EPS Est Next Year
|
1.34 |
|
Book Value (p.s.)
|
4.48 |
|
Profit Margin (%)
|
3.7 |
|
Operating Margin (%)
|
11.3 |
|
Return on Assets (ttm)
|
2 |
|
Return on Equity (ttm)
|
3.5 |
|
Qtrly Rev. Growth
|
-8.5 |
|
Gross Profit (p.s.)
|
2.85 |
|
Sales Per Share
|
7.17 |
|
EBITDA (p.s.)
|
1.14 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
597 (M) |
|
Levered Free Cash Flow
|
64 (M) |
Stock Valuations |
|
PE Ratio
|
85.64 |
|
PEG Ratio
|
1.8 |
|
Price to Book value
|
2.67 |
|
Price to Sales
|
1.67 |
|
Price to Cash Flow
|
13.8 |
Stock Dividends |
|
Dividend
|
0.46 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
3.8% |
|
Dividend Pay Date
|
2021-06-13 |
|
Ex-Dividend Date
|
2021-06-02 |
|
7 Binary Options
|
|
Your Ad Here
|
|
